Detalles de la búsqueda
1.
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Value Health
; 25(2): 203-214, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35094793
2.
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Value Health
; 24(3): 377-387, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33641772
3.
Real-world persistence with dupilumab among adults with atopic dermatitis.
Ann Allergy Asthma Immunol
; 126(1): 40-45, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32739313
4.
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Future Oncol
; 17(5): 611-627, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33052055
5.
Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
J Infect Dis
; 221(8): 1256-1270, 2020 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31165865
6.
Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection.
J Infect Dis
; 221(8): 1244-1255, 2020 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982895
7.
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Acta Derm Venereol
; 99(10): 851-857, 2019 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31099402
8.
Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.
Trop Med Int Health
; 21(2): 176-82, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26610176
9.
Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis.
BMC Health Serv Res
; 16: 304, 2016 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27461265
10.
Estimating the Public Health Burden Associated With Adverse Pregnancy Outcomes Resulting From Syphilis Infection Across 43 Countries in Sub-Saharan Africa.
Sex Transm Dis
; 42(7): 369-75, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26222749
11.
Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States.
J Thromb Thrombolysis
; 39(4): 508-15, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25371108
12.
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Eur Heart J
; 35(28): 1897-906, 2014 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-24513791
13.
Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis.
PLoS Med
; 10(11): e1001545, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24223524
14.
Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010.
BMC Nephrol
; 14: 132, 2013 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-23802885
15.
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
Eur J Prev Cardiol
; 30(17): 1874-1880, 2023 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314419
16.
Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda.
Bull World Health Organ
; 90(8): 595-603, 2012 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22893743
17.
Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.
BMC Public Health
; 12: 736, 2012 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22943068
18.
Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
J Manag Care Spec Pharm
; 28(5): 555-565, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35238626
19.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Ther Adv Med Oncol
; 14: 17588359221105024, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35747163
20.
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Front Oncol
; 12: 1081729, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-37082098